TipRanks
Advertisement
Advertisement

DE:87S Stock Latest News

Roivant Shareholders Approve Directors and Governance Matters
Company AnnouncementsRoivant Shareholders Approve Directors and Governance Matters
4d ago
8K
ROIV
Roivant Sciences initiated with a Buy at Stifel
PremiumThe Fly
Roivant Sciences initiated with a Buy at Stifel
6d ago
ROIV
Roivant Sciences price target raised to $55 from $50 at TD Cowen
PremiumThe Fly
Roivant Sciences price target raised to $55 from $50 at TD Cowen
13d ago
ROIV
Roivant Sciences price target raised to $46 from $42 at Guggenheim
PremiumThe Fly
Roivant Sciences price target raised to $46 from $42 at Guggenheim
13d ago
ROIV
Roivant Sciences price target raised to $47 from $41 at H.C. Wainwright
PremiumThe Fly
Roivant Sciences price target raised to $47 from $41 at H.C. Wainwright
14d ago
ROIV
Roivant Sciences rises 18.9%
PremiumThe FlyRoivant Sciences rises 18.9%
14d ago
ROIV
Midday Fly By: Amazon dominates headlines with Qualcomm pact, cargo flight crash
Premium
The Fly
Midday Fly By: Amazon dominates headlines with Qualcomm pact, cargo flight crash
14d ago
GE
ABM
Roivant Sciences price target raised to $52 from $42 at Jefferies
Premium
The Fly
Roivant Sciences price target raised to $52 from $42 at Jefferies
14d ago
ROIV
Roivant Sciences rises 17.6%
PremiumThe Fly
Roivant Sciences rises 17.6%
14d ago
ROIV
Roivant advances mosliciguat with positive Phase 2 results
PremiumCompany Announcements
Roivant advances mosliciguat with positive Phase 2 results
14d ago
8K
ROIV
Morning Movers: Novartis slumps after HARBOR study misses primary endpoint
PremiumThe Fly
Morning Movers: Novartis slumps after HARBOR study misses primary endpoint
14d ago
BSX
HLF
Roivant Sciences up 21% to $42.50 after Phase 2 PHocus trial met endpoint
PremiumThe Fly
Roivant Sciences up 21% to $42.50 after Phase 2 PHocus trial met endpoint
14d ago
ROIV
Roivant Sciences announces ‘positive’ results from Phase 2 PHocus clinical trial
PremiumThe FlyRoivant Sciences announces ‘positive’ results from Phase 2 PHocus clinical trial
14d ago
ROIV
Lisraya Pricing Upside and Measured Launch Drive Modest Roivant Target Increase to $37.50, Supporting Hold Rating Amid Balanced Risk/Reward
Premium
Ratings
Lisraya Pricing Upside and Measured Launch Drive Modest Roivant Target Increase to $37.50, Supporting Hold Rating Amid Balanced Risk/Reward
22d ago
ROIV
Roivant wins FDA nod for LISRAYA dermatomyositis therapy
Premium
Company Announcements
Roivant wins FDA nod for LISRAYA dermatomyositis therapy
25d ago
8K
ROIV
Douglas Tsao Reiterates Buy on Lisraya Maker, Citing Strong VALOR Data and Steroid-Sparing Profile; Maintains $41 Price Target
PremiumRatings
Douglas Tsao Reiterates Buy on Lisraya Maker, Citing Strong VALOR Data and Steroid-Sparing Profile; Maintains $41 Price Target
25d ago
ROIV
Roivant Gains FDA Approval for LISRAYA Dermatomyositis Therapy
PremiumCompany Announcements
Roivant Gains FDA Approval for LISRAYA Dermatomyositis Therapy
26d ago
8K
ROIV
Priovant Therapeutics announces FDA approval of Lisraya
PremiumThe Fly
Priovant Therapeutics announces FDA approval of Lisraya
26d ago
ROIV
Roivant Sciences Earnings Call: Cash-Rich, Catalyst-Heavy
PremiumCompany Announcements
Roivant Sciences Earnings Call: Cash-Rich, Catalyst-Heavy
1M ago
ROIV
Roivant Sciences price target raised to $37 from $35 at BofA
PremiumThe FlyRoivant Sciences price target raised to $37 from $35 at BofA
1M ago
ROIV
Roivant Sciences price target raised to $46 from $42 at Citi
Premium
The Fly
Roivant Sciences price target raised to $46 from $42 at Citi
1M ago
ROIV
Roivant Sciences price target raised to $42 from $36 at Guggenheim
Premium
The Fly
Roivant Sciences price target raised to $42 from $36 at Guggenheim
2M ago
ROIV

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >